Ticker: COGT

Cogent Biosciences, Inc. (NASDAQ: COGT) has released its latest financial results for the second quarter ending June 30, 2025, showcasing both challenges and advancements in its ongoing clinical trials and operations. Key Financial Highlights: Net Loss: The company reported a net loss of $73.5 m...

Cogent Biosciences, Inc. (NASDAQ: COGT) is currently navigating significant developments in its business, primarily in research and clinical trials. Their main product candidate, bezuclastinib, targets genetic mutations involved in serious conditions like Systemic Mastocytosis (SM) and gastrointe...